Clinical Trial Update: A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of hepatic arterial infusion chemotherapy with iparomlimab, tuvonralimab, and bevacizumab for initially potentially res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• HAIC (hepatic arterial infusion chemotherapy) (hepatic arterial infusion chemotherapy)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HCC | Phase 2 | Status: NOT_YET_RECRUITING